Fisetin benefits: the mouse study everyone cites, and the retest nobody does

Where the reputation came from

Limited evidence A 2018 study screened ten flavonoids for senolytic activity and found fisetin the most potent, reporting that acute or intermittent treatment of progeroid and aged mice improved healthspan and lifespan.^[1] It is a genuinely interesting paper and it is the origin of essentially every claim made for the compound since.

The mechanism it targets is real. Senescent cells accumulate with age, stop dividing without dying, and release inflammatory signals that disturb surrounding tissue.^[2] Their accumulation is one of the recognized hallmarks of aging, and clearing them genetically improves function in aged mice.^[3]

The retest almost nobody mentions

The Interventions Testing Program exists because single-laboratory lifespan results frequently fail to replicate. It tests compounds in genetically heterogeneous mice at multiple independent sites, and it has killed many promising candidates.

Fisetin went through it and did not produce a lifespan extension.^[4] That result is the single most decision-relevant fact about this compound, and it appears on essentially none of the pages selling it. A striking result from one lab, followed by a null result from the program designed to check such results, is a specific and familiar pattern.

We thought we were testing the notion that removing senescent cells would be good for you, and it turned out we were testing the notion that fisetin removes senescent cells.

What the human senolytic evidence actually is

Human senolytic research exists and is not about fisetin. A small pilot in patients with idiopathic pulmonary fibrosis using dasatinib with quercetin reported improvements in physical function measures.^[5] Related work in diabetic kidney disease reported reduced senescent cell burden in tissue after the same combination.^[6]

Those trials involved a handful of patients each, used a chemotherapy drug alongside a flavonoid, and measured markers or short-term function rather than health outcomes. Quercetin's own evidence summary describes a compound with poor bioavailability and modest effects.^[7] None of this transfers to a fisetin capsule.

The absorption problem

Fisetin is poorly water-soluble and poorly absorbed, which supplement pages acknowledge when recommending fat-paired or liposomal formulations. The acknowledgment is honest and the conclusion drawn from it usually is not.

Improving absorption from very low to slightly less low does not establish that a human achieves the tissue concentrations that produced the mouse results. That is the step the whole product category assumes and nobody has demonstrated.

What the fisetin benefits actually are today

Stated precisely: a mouse healthspan and lifespan result that a stricter program did not reproduce, extensive laboratory evidence of antioxidant and anti-inflammatory activity, preclinical neuroprotection data, and no human demonstration of anything.

That is not nothing. It is a legitimate research compound with a plausible mechanism. It is also a considerable distance from what the supplement pages describe, and the gap is filled with mouse data presented without the species attached.

We don't think they should be taken by the general public at this point, or prescribed by physicians.

How to think about the senolytic idea

Separate the idea from the compound. Senolytics are one of the more compelling concepts in aging biology, supported by genetic experiments that removed senescent cells and improved outcomes in mice. If any intervention in this field works, this class is a reasonable candidate.

Whether fisetin at an achievable oral dose is that intervention is a different question, and current evidence points away from it. Our review of the senolytic evidence covers the class properly, and the dosing page covers the intermittent protocols in circulation.

An honest position on fisetin

Cheap, apparently well tolerated, mechanistically interesting, and unproven in people with a failed lifespan retest behind it. If you take it, take it knowing that, rather than on the strength of a benefits list built from mouse data.

Eating strawberries is not a substitute and it is not worthless either, since the dietary pattern that contains them has better evidence than the capsule does. Our review of the wider supplement evidence ranks fisetin against the alternatives on exactly this standard.

Frequently asked questions

What are the benefits of fisetin?

In mice, senescent cell clearance with improvements in healthspan and lifespan. In cells, antioxidant and anti-inflammatory activity. In humans, essentially nothing has been demonstrated yet, and the rigorous mouse lifespan program that retested it did not reproduce the lifespan result.

Does fisetin actually work in humans?

Unknown. Small human trials of senolytic protocols exist, mostly using dasatinib with quercetin rather than fisetin, and they measured senescent cell markers rather than clinical outcomes. No trial has shown a health benefit from fisetin in people.

How long does it take for fisetin to work?

The question assumes a measurable effect. Senolytic protocols are dosed intermittently on the reasoning that clearing senescent cells is an occasional event rather than a daily one, and there is no accessible test to tell you whether anything happened.

What food is highest in fisetin?

Strawberries by a wide margin, then apples, persimmons, onions and grapes. Dietary amounts are a tiny fraction of supplement doses, which is one reason the food data and the supplement claims cannot be pooled.

Who should not take fisetin?

Anyone pregnant or breastfeeding, on the basis of absent evidence. Anyone on anticoagulants or with a bleeding disorder should ask first, since flavonoids can affect platelet function. Anyone on prescription medication should mention it, since interaction data are thin.

What is the best form of fisetin to take?

Liposomal and fat-paired formulations are marketed on the basis that fisetin absorbs poorly, which is true. What has not been shown is that any formulation reaches concentrations that do in a person what the mouse doses did in mice.

Can you take too much fisetin?

No upper limit has been established. Reported tolerability is good at supplement doses, and the senolytic protocols in circulation use high intermittent amounts that have not been tested for long-term safety in healthy people.

Is fisetin better than quercetin?

In the founding screen, fisetin was the most potent senolytic of ten flavonoids tested, which is where its reputation comes from. Quercetin has more human trial exposure, mostly in combination with dasatinib. Neither has a clinical outcome behind it.

Did fisetin extend lifespan in the ITP?

No, and this is the most important fact about it. The Interventions Testing Program, which tests compounds across multiple independent sites specifically to catch irreproducible results, did not find a lifespan extension with fisetin.

Why is it still popular then?

Because the original mouse result was striking, the mechanism is attached to a genuine hallmark of aging, and the compound is cheap, natural-sounding and unregulated. None of those is evidence that it works in people.

What is a senolytic anyway?

A compound that selectively kills senescent cells, which are damaged cells that stop dividing but do not die and release inflammatory signals. Their accumulation is a recognized hallmark of aging, and clearing them improves function in aged mice.

Is the senolytic idea itself sound?

The idea is among the best in the field, supported by genetic mouse experiments where clearing senescent cells improved healthspan. The uncertainty is entirely about whether any available compound does that safely and effectively in humans.

Are there human senolytic trials?

Yes, small ones. A pilot in idiopathic pulmonary fibrosis reported improved physical function measures, and a study in diabetic kidney disease reported reduced senescent cell burden in tissue. Both used dasatinib with quercetin, both were tiny, and neither was a fisetin trial.

What would change the picture for fisetin?

A human trial showing that a tolerable dose reduces senescent cell burden and improves a clinical outcome. Trials are running. Until they report, fisetin benefits in humans remain an extrapolation from a mouse study that a stricter program did not reproduce.